T cell therapy companies develop treatments that use a patient’s own or donor-derived immune cells to recognise and attack disease. These approaches are primarily used in cancer immunotherapy, with emerging applications across autoimmune and infectious diseases.
This category includes companies working on:
Browse 46 UK T cell therapy companies below.
Combinatorial stem cell screening platform for therapy development
Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial…
Specialist oncology clinical trial management for biotech and pharma
Karma Oncology is a specialist contract research organisation providing full-service and functional clinical trial management to biotechnology and pharmaceutical companies in…
Bispecific TCR therapies targeting HLA-Class II cancer antigens
Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II…
Pre-competitive biologics drug discovery platforms and services for partners
Alloy Therapeutics UK is the Cambridge-based research operation of Alloy Therapeutics, a biotechnology platform company providing pre-competitive drug discovery technologies and…
Cell and gene therapy supply chain orchestration software
TrakCel is a Welsh software company providing digital orchestration platforms for the management, tracking, and control of cell and gene therapy products across clinical and…
Automated bioreactor platform for GMP cell therapy manufacturing
Aglaris is a developer of automated cell manufacturing systems for advanced therapy medicinal products. Its flagship platform integrates real-time process monitoring, single-use…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel)…
Microfluidic avidity platform for preclinical cell therapy validation
Avigen is a contract research organisation providing preclinical validation services for cellular immunotherapies using a proprietary microfluidic platform. The platform measures…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic…
Next-generation CAR T-cell therapies for solid tumours
ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours. Its proprietary platform…
AI-native platform for cell culture process design and optimisation
Tolemy Bio Ltd is a company developing an AI-native platform for cell therapy process development and manufacturing optimisation. The platform ingests experimental and bioreactor…